Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines

Zeynep Ergüneş; Güldeniz Şekerci; Tuba Keskin; Samet Öz; Suat Tekin

doi:10.56766/ntms.2013146

Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines

Abstract

Asprosin is a peptide hormone secreted from white adipose tissue during fasting and plays a role in the regulation of energy metabolism. Its ability to cross the blood–brain barrier and exert effects on the central nervous system has attracted attention regarding neurological disorders and brain tumors. Recent studies suggest that asprosin may also be involved in tumor biology. This study investigated the effects of asprosin on cell viability and DNA damage in human glioblastoma (U87-MG) and mouse neuroblastoma (N2a) cell lines. Cells were treated with 1, 10, and 100 ng/mL asprosin. Cell viability was assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, while DNA damage was evaluated by the Comet assay. Data were analyzed using GraphPad Prism 9. One-way analysis of variance (ANOVA) followed by Tukey's post hoc test was used for statistical analysis, and p<0.05 was considered statistically significant. Asprosin reduced cell viability in both cell lines. A significant decrease was observed at 100 ng/mL in U87-MG cells and at 10 and 100 ng/mL in N2a cells. Comet assay results demonstrated that asprosin significantly increased DNA damage in both cell lines. In conclusion, asprosin exhibited cytotoxic and genotoxic effects in tumor cells. These findings suggest that asprosin may represent a potential therapeutic candidate for the treatment of glioblastoma and neuroblastoma.

Keywords

References

1.Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566-79.
2.Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23(12):1444-53.
3.Adam M, Ozcan S, Dalkilic S, et al. Modulation of Neuronal Damage in DRG by Asprosin in a High-Glucose Environment and Its Impact on miRNA181-a Expression in Diabetic DRG. Neurotox Res. 2024;42(1):5.
4.Onat E, Kocaman N, Balta H. The role of meteorin-like peptide and asprosin in colon carcinoma. Cureus. 2023;15(10): e47073.
5.Kerslake R, Hall M, Vagnarelli P, et al. A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer. Oncol Lett. 2021;22(3):650.
6.Kerslake R, Sisu C, Panfilov S, et al. Differential regulation of genes by the glucogenic hormone asprosin in ovarian cancer. J Clin Med. 2022;11(19):5942.
7.Kocaman N, Artaş G. Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma? Biotech Histochem. 2020;95(3):171-175.
8.Kocaman N, Yuksel EI, Demir B, Calik I, Cicek D. Two novel biomarker candidates for differentiating basal cell carcinoma from trichoblastoma; asprosin and meteorine like peptide. Tissue Cell. 2022;76:101752.

9.Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first‐phase insulin secretion. Mediators Inflamm. 2018;2018(1):9471583.
10.Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J. 2014;38(5):330.
11.Pouyan A, Ghorbanlo M, Eslami M, et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025;24(1):58.
12.D’Aprile S, Denaro S, Gervasi A, Vicario N, Parenti R. Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance. Frontiers in Cell and Developmental Biology. 2025;13:1535073.
13.Trejo-Solis C, Silva-Adaya D, Serrano-García N, et al. Role of glycolytic and glutamine metabolism reprogramming on the proliferation, invasion, and apoptosis resistance through modulation of signaling pathways in glioblastoma. Int J Mol Sci. 2023;24(24):17633.
14.Zhao J, Ma X, Gao P, et al. Advancing glioblastoma treatment by targeting metabolism. Neoplasia. 2024;51:100985.
15.Narsinh KH, Perez E, Haddad AF, et al. Strategies to improve drug delivery across the blood–brain barrier for glioblastoma. Curr Neurol Neurosci Rep. 2024;24(5):123-39.
16.Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36(3):437-49.
17.Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284-95.
18.Wulf AM, Moreno MM, Paka C, Rampasekova A, Liu KJ. Defining pathological activities of ALK in neuroblastoma, a neural crest-derived cancer. Int J Mol Sci. 2021;22(21):11718.
19.Becker J, Wilting J. WNT signaling, the development of the sympathoadrenal–paraganglionic system and neuroblastoma. Cell Mol Life Sci. 2018;75(6):1057-70.
20.Zafar A, Wang W, Liu G, et al. Molecular targeting therapies for neuroblastoma: progress and challenges. Med Res Rev. 2021;41(2):961-1021.
21.Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nature Reviews Clin Oncol. 2022;19(8):515-33.
22.Wachowska D, Respekta N, Kurowska P, Błasiak A, Dupont J, Rak A. Asprosin, a novel adipokine, in the mouse hypothalamus: expression and in vitro effect on GT1-7 cells proliferation and GnRH secretion. Preliminary data. Endocr Abstr. 2023;90:EP865.
23.Ozkaya SN, Keskin T, Tekin C, Tekin S, Beytur A. Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. Ann Med Res. 2023;30(6):727-32.
24.Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
25.Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89(2):271-77.
26.Horáková K, Šovčíková A, Seemannová Z, et al. Detection of drug-induced, superoxide-mediated cell damage and its prevention by antioxidants. Free Radic Biol Med. 2001;30(6):650-64.
27.Karataş MO, Tekin S, Alici B, Sandal S. Cytotoxic effects of coumarin substituted benzimidazolium salts against human prostate and ovarian cancer cells. J Chem Sci. 2019;131(8):69.
28.Koran K, Tekin Ç, Çalışkan E, Tekin S, Sandal S, Görgülü AO. Synthesis, structural and thermal characterizations and in vitro cytotoxic activities of new cyclotriphosphazene derivatives. Phosphorus, Sulfur, and Silicon and the Related Elements. 2017;192(9):1002-1011.
29.Klaude M, Eriksson S, Nygren J, Ahnström G. The comet assay: mechanisms and technical considerations. Mutation Research/DNA Repair. 1996;363(2):89-96.
30.Koran K, Çalışkan E, Öztürk DA, et al. The first peptide derivatives of dioxybiphenyl-bridged spiro cyclotriphosphazenes: In vitro cytotoxicity activities and DNA damage studies. Bioorg Chem. 2023;132:106338.
31.Hainaut P, Plymoth A. Cancer as a metabolic disease. Curr Opin Oncol. 2012;24(1):56-57.
32.Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021;10(5):1056.
33.Liao M, Yao D, Wu L, et al. Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer. Acta Pharm Sin B. 2024;14(3):953-1008.
34.Wang X-L, Wang J-X, Chen J-L, et al. Asprosin in the paraventricular nucleus induces sympathetic activation and pressor responses via cAMP-dependent ROS production. Int J Mol Sci. 2022;23(20):12595.
35.Chen S, Wang X, Qiu C-M, et al. Study of the role and mechanism of asprosin/spartin pathway in cardiac microvascular endothelial injury induced by diabete mellitus. Sichuan Da Xue Xue Bao Yi Xue Ban. 2019;50(6):827-34.
36.Zhang Z, Tan Y, Zhu L, et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. Life Sci. 2019;231:116554.
37.Keskin T, Korkmaz E, Yıldız A, Tekin Ç, Beytur A, Tekin S. Asprosin protects against ischemia/reperfusion-induced kidney injury in mice. J Mol Histol. 2025;56(5):265.

Details

Primary Language

English

Subjects

Public Health (Other)

Journal Section

Research Article

Authors

Zeynep Ergüneş
0000-0003-3041-0142
Türkiye

Güldeniz Şekerci
0000-0002-0811-4454
Türkiye

Tuba Keskin
0000-0002-9212-4021
Türkiye

Samet Öz
0000-0002-4549-4388
Türkiye

Suat Tekin ^*
0000-0002-2757-1802
Türkiye

Publication Date

October 29, 2026

Submission Date

August 10, 2026

Acceptance Date

September 24, 2026

Published in Issue

Year 2026 Volume: 7 Number: 3

DOI

https://doi.org/10.56766/ntms.2013146

IZ

https://izlik.org/JA64YK96RA

Cite

RIS / Bibtex

APA

Ergüneş, Z., Şekerci, G., Keskin, T., Öz, S., & Tekin, S. (2026). Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines. New Trends in Medicine Sciences, 7(3), 106-115. https://doi.org/10.56766/ntms.2013146

AMA

1.Ergüneş Z, Şekerci G, Keskin T, Öz S, Tekin S. Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines. New Trend Med Sci. 2026;7(3):106-115. doi:10.56766/ntms.2013146

Chicago

Ergüneş, Zeynep, Güldeniz Şekerci, Tuba Keskin, Samet Öz, and Suat Tekin. 2026. “Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines”. New Trends in Medicine Sciences 7 (3): 106-15. https://doi.org/10.56766/ntms.2013146.

EndNote

Ergüneş Z, Şekerci G, Keskin T, Öz S, Tekin S (October 1, 2026) Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines. New Trends in Medicine Sciences 7 3 106–115.

IEEE

[1]Z. Ergüneş, G. Şekerci, T. Keskin, S. Öz, and S. Tekin, “Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines”, New Trend Med Sci, vol. 7, no. 3, pp. 106–115, Oct. 2026, doi: 10.56766/ntms.2013146.

ISNAD

Ergüneş, Zeynep - Şekerci, Güldeniz - Keskin, Tuba - Öz, Samet - Tekin, Suat. “Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines”. New Trends in Medicine Sciences 7/3 (October 1, 2026): 106-115. https://doi.org/10.56766/ntms.2013146.

JAMA

1.Ergüneş Z, Şekerci G, Keskin T, Öz S, Tekin S. Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines. New Trend Med Sci. 2026;7:106–115.

MLA

Ergüneş, Zeynep, et al. “Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines”. New Trends in Medicine Sciences, vol. 7, no. 3, Oct. 2026, pp. 106-15, doi:10.56766/ntms.2013146.

Vancouver

1.Zeynep Ergüneş, Güldeniz Şekerci, Tuba Keskin, Samet Öz, Suat Tekin. Evaluation of the Effects of Asprosin on Cell Viability and DNA Damage on Human Glioblastoma and Mouse Neuroblastoma Cell Lines. New Trend Med Sci. 2026 Oct. 1;7(3):106-15. doi:10.56766/ntms.2013146